Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen ® and Synacthen Depot in the US from Novartis Pharma AG and Novartis AG. Subject to certain closing conditions, Questcor has also acquired rights to Synacthen ® and Synacthen Depot ® in certain countries outside the US Available in more than forty countries for multiple indications, Synacthen is a synthetic 24 amino acid melanocortin receptor agonist.
Questcor Pharmaceuticals acquires rights to Synacthen®